Additional file 1: of Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Table S1. Reasons for premature withdrawal (n = 294). Table S2. Most common planned CT therapies for patients with ST (analysis population; n = 1174). Table S3. Characteristics of treatment with Zarzio® during the study in patients with follow up (n = 1141). Table S4. Summary of adverse events (n = 62) experienced by ST patients during the study. (DOCX 22 kb)